Exploring the potential of fish oil (Omega-3 and Omega-6 Polyunsaturated Fats) as metabolic mediators for targeted cancer therapy

Isaac Sokoato MOMOH 1, *, Micheal Omeyiza IBRAHIM 1, Victoria Sokolayame EMMANUEL 2, Emieseimokumo NUMONDE 3 and Peter Ayomide AKOMOLAFE 4

1 Department of Biochemistry, Faculty of Science, Confluence University of Science and Technology, Osara, Kogi State, Nigeria.
2 Department of fisheries and Aquaculture Faculty of Agriculture Kogi State University Ayingba Nigeria.
3 Department of Biochemistry, Faculty of Science, Rivers State University, Nigeria.
4 Department of Science Laboratory Technology, Federal Polytechnic, Ayede, Oyo State, Nigeria.
 
Review
International Journal of Life Science Research Archive, 2024, 06(01), 090–095​.
Article DOI: 10.53771/ijlsra.2024.6.1.0032
Publication history: 
Received on 01 January 2024; revised on 13 February 2024; accepted on 15 February 2024
 
Abstract: 
Cancer mortality and incidence are both sharply increasing on a global scale. GLOBOCAN estimates that in 2020, there were around 10.0 million cancer-related deaths and nearly 19.3 million new cancer diagnoses, making cancer the top cause of death globally and a significant impediment to improving life expectancy. Cancer cannot be completely cured, though. However, supplements containing polyunsaturated fatty acids with marine origins, such as EPA and DHA, are frequently taken. Fish oil (above 3 grams per day) and EPA/DHA (above 1 and above 0.8 grams per day) have been shown to have good clinical effects, indicating that they may have the potential to be an effective adjuvant to chemotherapy and may alleviate some of the harmful consequences of cancer. This review is aimed at examining the importance of Omega-3 PUFAs as metabolic mediators and their impact on cancer.
 
Keywords: 
DHA (docosahexaenoic acid); ALA (alpha-linolenic acid); EPA (eicosapentaenoic acid); PUFAs (polyunsaturated fatty acids); NF-KB (Nuclear Factor Kappa light chain enhancer of activated B cells).
 
Full text article in PDF: